WASHINGTON: US biotech company Moderna announced on Wednesday that it has begun clinical trials of a booster dose of vaccine designed specifically to combat the Omicron variant of Covid-19.
The trials will involve a total of 600 adults — half of whom have already received two doses of Moderna’s vaccine at least six months ago, and half of whom have received two doses plus the previously authorized booster dose.
The booster specifically targeting Omicron will therefore be evaluated as both a third and a fourth dose.
The trials will involve a total of 600 adults — half of whom have already received two doses of Moderna’s vaccine at least six months ago, and half of whom have received two doses plus the previously authorized booster dose.
The booster specifically targeting Omicron will therefore be evaluated as both a third and a fourth dose.
!function(f,b,e,v,n,t,s) {if(f.fbq)return;n=f.fbq=function(){n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}; if(!f._fbq)f._fbq=n;n.push=n;n.loaded=!0;n.version=’2.0′; n.queue=[];t=b.createElement(e);t.async=!0; t.src=v;s=b.getElementsByTagName(e)[0]; s.parentNode.insertBefore(t,s)}(window, document,’script’, ‘https://connect.facebook.net/en_US/fbevents.js’); fbq(‘init’, ‘593671331875494’); fbq(‘track’, ‘PageView’);
More News
US emphasises importance of ex-Pak PM Imran Khan’s safety in jail – Times of India
‘Taboo’: French women speak out on rapes by US soldiers during WWII – Times of India
Russia used over 50 missiles and 20 drones in overnight attack on Ukraine’s infrastructure, Zelenskyy says – Times of India